Allarity Therapeutics (ALLR) vs Biofrontera (BFRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed Allarity Therapeutics (ALLR) over the past year, losing 9.0% versus a loss of 42.2%. Allarity Therapeutics is the larger company by market cap ($15.8 million vs $14.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | BFRI |
|---|---|---|
| Share price | $0.99 | $0.97 |
| Market cap | $15.75M | $14.41M |
| 1-day change | +0.82% | +5.57% |
| YTD return | -9.08% | +61.19% |
| 1-year return | -42.24% | -9.03% |
| Forward P/E | — | 2.26 |
| EPS (TTM) | $-0.79 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $1.66 |
| 52-week low | $0.769 | $0.555 |
| Distance from 52-week high | -46.20% | -41.57% |
| Analyst consensus | none | none |
| Avg. price target upside | +1011.11% | +518.56% |
| Average volume | 90.75K | 547.45K |
| Shares outstanding | 15.91M | 14.85M |
| Employees | 7 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed ALLR by 33.2 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
ALLR vs BFRI FAQ
Which is bigger, Allarity Therapeutics or Biofrontera?
Allarity Therapeutics (ALLR) is larger, with a market capitalization of $15.75M compared with $14.41M for Biofrontera (BFRI).
Which stock has performed better over the past year, ALLR or BFRI?
BFRI returned -9.03% over the past 12 months, compared with -42.24% for ALLR (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Biofrontera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.